Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Taligen Therapeutics

Request full access

Focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases

Cambridge, United StatesFounded 2004Biotech & Life Sciences

About Taligen Therapeutics

Taligen Therapeutics was a development-stage biotechnology firm founded in 2004 and headquartered in Cambridge, Massachusetts. The company focused on creating new treatments for immune and inflammatory diseases by regulating the complement system, a crucial part of the immune pathway. Its core business revolved around developing a pipeline of protein therapeutics, including monoclonal antibodies and fusion proteins, designed to selectively target and control excessive inflammation in affected tissues. This approach was applicable to a wide range of conditions, from genetic and orphan diseases to large-market ailments like age-related macular degeneration (AMD).

The company's strategy centered on its proprietary technology related to complement biology. Taligen's lead product candidate was TT30, a novel fusion protein that selectively binds to complement-activated cells to regulate the immune system locally. This product and other related compounds were covered by U.S. Patent No. 7,759,304, which was exclusively licensed to Taligen from the Medical University of South Carolina and the University of Colorado. The company's business model was to use its development platform to achieve proof-of-concept in smaller trials for rare diseases and then form partnerships with larger pharmaceutical companies for broader market applications.

Under the leadership of President and CEO Abbie Celniker, Ph.D., who joined in 2008, Taligen secured significant venture capital funding. Dr. Celniker brought extensive experience from senior R&D and leadership roles at companies like Novartis and Millennium Pharmaceuticals. The company raised a total of $101 million over three funding rounds, with investors including Alta Partners, Sanderling Ventures, and Blackstone. A significant milestone was the company's acquisition by Alexion Pharmaceuticals in January 2011 for an upfront cash payment of $111 million. The deal also included potential future payments based on achieving clinical and regulatory milestones for up to six products. Following the acquisition, Taligen's scientific team became the core of Alexion's new Translational Medicine Group, also headed by Dr. Celniker, to continue the development of Taligen's promising preclinical compounds.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2004
Headquarters
Cambridge, United States
Employees
3
Open positions
None listed
Dealroom signal
59.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Inflammatory Diseases, Spinout, Alternative Protein, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jan 2011 $111M $111M Alexion Pharmaceuticals —
SERIES BOther financing Aug 2010 $10M $40M Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Taligen Therapeutics website traffic

Latest recorded traffic for Taligen Therapeutics is 0 monthly website visits. Taligen Therapeutics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Taligen Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Taligen Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • High Country Venture
  • Alta Partners

Other known investors4 additional known investors

  • Alexion Pharmaceuticals
  • Medical University of South Carolina
  • National Jewish Health Respiratory Institute
  • University of Colorado
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Taligen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Taligen Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.